New Clinical Trial Finds Uthever NMN to Increase NAD+ By 38%, Reduce Insulin Resistance, and Improve Quality of Life

• This clinical trial tested the effects of Uthever NMN in a group of 66 healthy adults between the ages of 40 and 65. 

• The participants were supplemented with either 300 mg NMN per day for 60 days or placebo.

• After 30 days, the Uthever NMN group already showed a substantial increase in NAD+/NADH levels, at 11.3% above baseline, whereas the placebo group showed no increase.

• After 60 days, the results were even greater — the Uthever NMN group increased NAD+/NADH levels by 38% from baseline, while the placebo group increased their levels by 14.3%.

• These results show that ProHealth Uthever NMN is the first NMN clinically proven to boost NAD+ in humans. 

• Further, the Uthever NMN group showed a 6.5% increase in scores on questions about quality of life and physical functioning, compared to 3.4% in the placebo group. 

• Lastly, the Uthever NMN group improved insulin sensitivity, as measured by the HOMA IR Index. Compared to the placebo group, which increased their insulin resistance by 30.6%, the NMN group only saw a rise of 0.6%, indicating much greater insulin sensitivity. 

This abstract was published in the journal Frontiers in Aging in March 2022: 

Objective: The purpose of the study was to evaluate the anti-ageing effect of NMN and its safety in a double-blind, parallel, randomized controlled clinical trial.

Methods: The study was carried out in 66 healthy subjects between ages 40 to 65 years, instructed to take two capsules (each containing 150 mg. NMN or starch powder) once a day after breakfast for 60 days daily.

Results: At day 30 NAD+/NADH levels in the serum showed noteworthy increase i.e. by 11.3% whereas the placebo group had shown no change at all. At end of study i.e. day 60 the NAD+/NADH levels were increased further by 38% compared to baseline against mere 14.3% in the placebo group. In case of SF 36, at day 60 the Uthever group showed a rise of 6.5% whereas the placebo group was merely raised by 3.4%. At the end of the study, mean HOMA IR Index showed a rise of 0.6% among Uthever group and 30.6% among Placebo group from baseline.

Conclusion: The rise in the levels of NAD+/NADH at Day 30 and Day 60 illustrated the potential of Uthever to raise the levels of NAD+ in the cells, which is linked to higher energy levels and anti-aging effect. Increased sensitivity to insulin has also been linked to anti-aging. There was no noteworthy change in HOMA score in the Uthever group whereas there was a noteworthy rise in the placebo group, demonstrating the anti-aging effect of Uthever as in its absence the parameter worsened.